Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.OCUP · Entity 5892 | Director | November 19, 2020 | November 26, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date November 19, 2020 · Filed November 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 487,029 |
Reported balance
After 2020-11-19 transaction · row 1
1 source rowRow 1 · 2020-11-19 · Purchase · Acquired 1,771 · Balance 487,029 F1: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2025-11-19 | Direct | 2,679 |
Reported balance
After 2020-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-19 · Purchase · Acquired 2,679 · Balance 2,679 F2: Subject to adjustment based on certain price reset provisions. F1: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-01-28 | Direct | 315 |
Reported balance
After 2020-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-19 · Purchase · Acquired 315 · Balance 315 F2: Subject to adjustment based on certain price reset provisions. F1: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000.
F2: Subject to adjustment based on certain price reset provisions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2020 Filed Nov 26, 2020 00:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries B Warrant (right to buy) · Derivative | 315 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001140361-20-026650 · form4.xml · derivative · entry 3 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315 Underlying: Common Stock · 315 shares Expires 2022-01-28 F2 · shares: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 00:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries A Warrant (right to buy) · Derivative | 2,679 | Not disclosed Strike: $4.48 | Not disclosed |
DisclosureSEC source: 0001140361-20-026650 · form4.xml · derivative · entry 2 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,679 Underlying: Common Stock · 2,679 shares Expires 2025-11-19 F2 · derivative.exercise_price: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 00:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 1,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-026650 · form4.xml · nonDerivative · entry 1 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,029 F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $10,000. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:50 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025517 · form4.xml · derivative · entry 1 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-11-11 F1 · derivative.exercise_date: Vesting in 12 equal monthly increments beginning on November 30, 2020. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:47 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 31,695 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001596771-20-000114 · primary_doc.xml · derivative · entry 3 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,695 Underlying: Common Stock · 31,695 shares Expires 2029-12-27 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F3 · derivative.exercise_date: 3,803 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:47 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 35,663 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001596771-20-000114 · primary_doc.xml · derivative · entry 2 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,663 Underlying: Common Stock · 35,663 shares Expires 2028-10-01 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:47 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 485,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-20-000114 · primary_doc.xml · nonDerivative · entry 1 MEYER ALAN R · CIK 0001212162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,258 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.